By Pierre Bertrand

Novartis AG said Thursday that a Phase 3 trial for its drug iptacopan has met its primary endpoint of boosting hemoglobin levels.

The Swiss pharma company said the trial showed that patients treated twice daily with the drug achieved clinically meaningful hemoglobin-level increases without the need for blood transfusions at 24 weeks.

Iptacopan is a treatment for blood disease paroxysmal nocturnal hemoglobinuria, which causes the premature death of red blood cells. Patients with PNH suffer anemia, fatigue and require blood transfusions.

Write to Pierre Bertrand at pierre.bertrand@wsj.com

(END) Dow Jones Newswires

December 08, 2022 01:57 ET (06:57 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024 Click aqui para mais gráficos Novartis.